Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

This study has been completed.
National Cancer Institute (NCI)
AEterna Zentaris
Information provided by (Responsible Party):
University of Southern California Identifier:
First received: June 30, 2010
Last updated: February 3, 2017
Last verified: February 2017

June 30, 2010
February 3, 2017
November 2, 2010
February 2, 2017   (Final data collection date for primary outcome measure)
Clinical benefit defined as non-progression with no dose-limiting toxicity or other toxicity requiring termination of treatment [ Time Frame: At 3 months up to 24 months ]
Same as current
Complete list of historical versions of study NCT01240629 on Archive Site
  • Time to overall disease progression [ Time Frame: Up to 24 months ]
  • Response for patients with measurable disease based on the Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: At 3 months up to 24 months ]
  • To assess the prostate specific antigen (PSA) response rate in patients treated with AN-152 [ Time Frame: At 3 months up to 24 months ]
  • Time to PSA progression [ Time Frame: Up to 24 months ]
  • Number of participants with adverse events as a measure of safety and tolerability [ Time Frame: At 3 weeks up to 72 weeks ]
  • Pain palliation defined as a 2-point decrease in pain scale of 1-10 without concomitant increase in analgesic medication use (Correlative study) [ Time Frame: At 3 weeks up to 72 weeks ]
  • Overall survival [ Time Frame: Up to 2 years ]
Same as current
Not Provided
Not Provided
Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
A Phase I/II Trial of AN-152 [AEZS-108) in Castration- and Taxane-Resistant Prostate Cancer

This is a research study for advanced prostate cancer. An experimental drug called AN-152 (also known as AEZS-108) will be used. The purpose of this study is to test the safety, tolerability and benefits of an experimental drug called AN-152.

The participants tumor will be tested for expression of this receptor (using an old biopsy). If the participants cancer does not have this receptor, participants will not be eligible to participant in this study.

AN-152 (AEZS-108) is administered intravenously (IV) over 2 hours and will be given at the specified dose every 3 weeks. Premedication with dexamethasone 8mg is recommended.

Participants will continue treatment until death, disease progression, unacceptable toxicity, participants refusal, treatment delay >3 weeks, or the completion of 6 cycles. Continuation beyond 6 cycles is left at the discretion of the study doctor.

The study is planned to last 2 years. Up to 55 (up to 18 for the Phase I portion, up to 37 for the Phase II portion).

Not Provided
Phase 1
Phase 2
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
  • Prostate Cancer
  • Hormone-resistant Prostate Cancer
  • Recurrent Prostate Cancer
  • Stage IV Prostate Cancer
  • Other: laboratory biomarker analysis
    Correlative study
  • Other: questionnaire administration
    Correlative study
  • Drug: doxorubicin-GnRH agonist conjugate AEZS-108
    Given IV
    Other Names:
    • AEZS-108
    • doxorubicin-LHRH agonist conjugate AEZS-108
Experimental: Arm I
Patients receive doxorubicin-GnRH agonist conjugate AEZS-108 intravenously (IV) over 2 hours once every 21 days (21 days = 1 cycle). Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
  • Other: laboratory biomarker analysis
  • Other: questionnaire administration
  • Drug: doxorubicin-GnRH agonist conjugate AEZS-108
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
February 2, 2017
February 2, 2017   (Final data collection date for primary outcome measure)


  • Histologically or cytologically confirmed prostate cancer
  • Measurable disease on computer tomography (CT) scan or evaluable disease with an elevated prostate specific antigen (PSA)
  • Documented progression on (a) at least one prior hormone treatment, which must have incorporated luteinizing hormone-releasing hormone (LH- RH)agonist therapy AND (b) at least one chemotherapy regimen, which must have been taxane based
  • Progression may be demonstrated by PSA (defined by a 25% increase in the PSA from its most recent treatment nadir, confirmed with a second measurement at least 4 weeks later) or radiologic criteria (defined by radiologic documentation of a new lesion or a >= 20% increase in the sum of the diameters of previously noted measurable lesions)
  • Palliative radiation therapy (RT) for metastatic disease is allowed only if =< 25% of total body bone marrow was irradiated and =< 35Gy administered to the pericardial area
  • 28 days must have elapsed since completion of RT with bone marrow recovery
  • Soft tissue disease irradiated in the prior 2 months may not be designated as measurable disease
  • Eastern Cooperative Oncology Group (ECOG) performance score of 0-2
  • Adequate bone marrow function, defined by ANC >= 1000/ul, hemoglobin >= 8.0 g/dL and platelet count >= 75,000/ ul
  • Adequate renal function, defined by serum creatinine =< 1.5x the upper limit of normal (ULN)
  • Adequate hepatic function, defined by bilirubin =< 1.5 mg/dL AND alkaline phosphatase =< 3x ULN for the reference lab (=< 5x ULN for patients with known hepatic metastases and no limit for patients with known bone metastases) AND AST and ALT =< 3x ULN (=< 5x the ULN for patients with known hepatic metastases)
  • Must have recovered from acute and late effects of any prior surgery, radiotherapy or other anti-neoplastic therapy
  • Patients or their legal representatives must be able to read,understand, and provide informed consent
  • Men of childbearing potential must consent to use barrier contraception while on treatment and for 90 days thereafter
  • Willingness to discontinue LH-RH analogue therapy and for the duration of the study


  • Ongoing use of an LH-RH agonist (or antagonist)
  • Patients who agree to stop LH-RH agonist therapy will be eligible but may need to wait until their required washout period is over
  • Patients whose washout period is more than 6 weeks will not be eligible
  • Duration of washout period varies with the formulation of the LH-RH agonist being used and should be 2 weeks after the next dose would be scheduled. Specifically: a) For patients receiving a monthly formulations of LH-RH agonist, 6 weeks must pass from the last dose before eligibility; b) For patients receiving a 3-month depot formulation of LH-RH agonist, 14 weeks must pass from the last dose before eligibility; c) For patients receiving a 4- month depot formulation of LH-RH agonist, 18 weeks must pass from the last dose before eligibility; d) For patients receiving a 6- month depot formulation of LH-RH agonist, 26 weeks must pass from the last dose before eligibility; e) For patients with an annual LH-RH implant, 2 weeks must pass after removal of the implant before eligibility
  • Presence of an active infection or fever within 3 days of the first scheduled protocol treatment
  • Presence of parenchymal brain metastases
  • Patients with neurological symptoms must have a CT or magnetic resonance imaging (MRI)scan of the brain showing no metastases within 60 days of enrollment
  • History of prior malignancy within the past 5 years with the exception of curatively treated basal cell or squamous cell carcinoma of the skin or superficial bladder
  • Patients with known hypersensitivity to any of the components of AN-152 including doxorubicin and LH-RH agonists
  • Patients who received radiotherapy within 4 weeks of entry
  • Patients who received treatment with strontium-89 or samarium-153 are excluded, except prior samarium will be allowed provided it was administered more than 1 year ago and/or the patient has demonstrated the ability to receive cytotoxic chemotherapy without excess of myelosuppression after receiving samarium.
  • Patients with a history of unstable or newly diagnosed angina pectoris, documented history of current serious arrhythmia or congestive heart failure or recent myocardial infarction (within 6 months of enrollment)
  • Left ventricular ejection fraction (EF) < 50%
  • Prior exposure to anthracyclines or anthracenediones including doxorubicin, daunorubicin, and mitoxantrone
  • Major surgery within the last 2 weeks
  • Receiving concurrent investigational therapy or have received investigational therapy within 30 days of the first scheduled day of protocol treatment (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication)
  • Known HIV or hepatitis B or C infection
  • Life expectancy < 3 months
  • Presence of any other medical condition, including mental illness or substance abuse, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with interpretation of the results
  • Prior treatment with AN-152
  • Lack of ability or willingness to give informed consent
  • Anticipated non-availability for study visits/procedures
Sexes Eligible for Study: Male
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
University of Southern California
University of Southern California
  • National Cancer Institute (NCI)
  • AEterna Zentaris
Principal Investigator: Jacek Pinski University of Southern California
University of Southern California
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP